person · Reporting owner
ANDREWS RONALD ASBURY
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERENOME, INC.CNSY · Entity 7637 | Director | October 01, 2026 | October 01, 2026 |
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | Director · Former CEO | December 01, 2022 | December 10, 2022 |
| Precipio, Inc.PRPO · Entity 7207 | Director | October 15, 2025 | January 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERENOME, INC.
Report date October 01, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,843 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Exercise / conversion · Acquired 921 · Balance 1,843 F2: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,843 |
Reported balance
After 2026-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-01 · Exercise / conversion · Disposed 921 · Balance 1,843 F2: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.
F2: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.
Insight Molecular Diagnostics Inc.
Report date December 01, 2022 · Filed December 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 583,212 |
Reported balance
After 2022-12-01 transaction · row 1
1 source rowRow 1 · 2022-12-01 · Exercise / conversion · Acquired 250,000 · Balance 583,212 |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.10 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-01 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.40 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-01 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.51 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-01 · Disposition to issuer · Disposed 950,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.68 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-12-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.34 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-12-01 · Disposition to issuer · Disposed 500,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.15 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-12-01 · Disposition to issuer · Disposed 300,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.15 | Direct | 281,250 |
Reported balance
After 2022-12-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-12-01 · Disposition to issuer · Disposed 93,750 · Balance 281,250 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-12-07 | Direct | 50,000 |
Reported balance
After 2022-12-07 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-12-07 · Grant · Acquired 50,000 · Balance 50,000 F3: Options vest (and thereby become exercisable) as follows: (i) one-third on December 31, 2022, (ii) one-third on January 31, 2023, and (iii) one-third on February 28, 2023 (each such date, a "Vesting Date"), in each case, subject to the Reporting Person's continuous service as a consultant on each applicable Vesting Date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-12-01 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 250,000 |
Reported balance
After 2022-12-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-12-01 · Disposition to issuer · Disposed 250,000 · Balance 250,000 F2: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-12-01 · Exercise / conversion · Disposed 250,000 · Balance 0 F2: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022.
F2: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022.
F3: Options vest (and thereby become exercisable) as follows: (i) one-third on December 31, 2022, (ii) one-third on January 31, 2023, and (iii) one-third on February 28, 2023 (each such date, a "Vesting Date"), in each case, subject to the Reporting Person's continuous service as a consultant on each applicable Vesting Date.
Precipio, Inc.
Report date October 15, 2025 · Filed January 20, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,796 |
Reported balance
After 2025-10-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-10-15 · Grant · Acquired 568 · Balance 15,796 F1: This Form 4/A is being filed to correct the reporting person's aggregate beneficial ownership, which was understated by 88 shares in the original Form 4 filed on October 15, 2025 due to an administrative reporting error. No additional transactions occurred other than those previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4/A is being filed to correct the reporting person's aggregate beneficial ownership, which was understated by 88 shares in the original Form 4 filed on October 15, 2025 due to an administrative reporting error. No additional transactions occurred other than those previously reported.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Oxford Immunotec Global PLC
Report date March 08, 2021 · Filed March 12, 2021
Section 16 reporting ended · disclosed 2021-03-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 1
1 source rowRow 1 · 2021-03-08 · Disposition to issuer · Disposed 4,081 · Balance 0 F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2026-06-28 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.46 · Expires 2027-06-06 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.49 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.44 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.50 · Expires 2025-11-04 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-08 · Disposition to issuer · Disposed 14,914 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.50 · Expires 2025-11-04 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2030-06-24 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-03-08 · Disposition to issuer · Disposed 9,494 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2021 Filed Jul 3, 2021 01:32 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionRestricted Stock Units · Derivative | 65,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-016130 · ownership.xml · derivative · entry 3 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 65,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Restricted Stock Units vested on July 1, 2021. F2 · derivative.expiration_date: Restricted Stock Units vested on July 1, 2021. Read SEC document |
| July 01, 2021 Filed Jul 3, 2021 01:32 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Tax withholdingCommon Stock, no par value | 15,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-016130 · ownership.xml · nonDerivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,212 F1 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 65,000 Restricted Stock Units. Read SEC document |
| July 01, 2021 Filed Jul 3, 2021 01:32 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Stock, no par value | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-016130 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 17:59 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Tax withholdingCommon Stock, no par value | 25,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-015984 · ownership.xml · nonDerivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,046 F1 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 106,221 Restricted Stock Units. Read SEC document |
| May 07, 2021 Filed Jul 2, 2021 17:59 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionRestricted Stock Units · Derivative | 106,221 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-015984 · ownership.xml · derivative · entry 3 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 106,221 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Restricted Stock Units vested on May 7, 2021. F2 · derivative.expiration_date: Restricted Stock Units vested on May 7, 2021. Read SEC document |
| May 07, 2021 Filed Jul 2, 2021 17:59 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Stock, no par value | 106,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-015984 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 21:17 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 11,000 | $4.79 | $52,702.10 |
DisclosureSEC source: 0001493152-21-006546 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,698 F1 · price: The shares were purchased at various prices ranging from $4.76 to $4.81. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:35 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,494 | $9.04 Strike: $12.96 | $85,825.76 |
DisclosureSEC source: 0001140361-21-008340 · form4.xml · derivative · entry 8 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,494 shares Expires 2030-06-24 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:35 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $9.50 Strike: $12.50 | $70,841.50 |
DisclosureSEC source: 0001140361-21-008340 · form4.xml · derivative · entry 7 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2025-11-04 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:35 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,914 | $9.50 Strike: $12.50 | $141,683.00 |
DisclosureSEC source: 0001140361-21-008340 · form4.xml · derivative · entry 6 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,914 shares Expires 2025-11-04 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:35 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $7.56 Strike: $14.44 | $56,374.92 |
DisclosureSEC source: 0001140361-21-008340 · form4.xml · derivative · entry 5 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2029-06-18 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:35 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $7.51 Strike: $14.49 | $56,002.07 |
DisclosureSEC source: 0001140361-21-008340 · form4.xml · derivative · entry 4 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2028-06-19 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:35 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $7.54 Strike: $14.46 | $56,225.78 |
DisclosureSEC source: 0001140361-21-008340 · form4.xml · derivative · entry 3 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2027-06-06 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:35 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $13.35 Strike: $8.65 | $99,550.95 |
DisclosureSEC source: 0001140361-21-008340 · form4.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2026-06-28 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:35 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerOrdinary Shares | 4,081 | $22.00 | $89,782.00 |
DisclosureSEC source: 0001140361-21-008340 · form4.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 20:08 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantEmployee Stock Option (right to buy) · Derivative | 5,171 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-21-032065 · tm215617d2_4.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5.171 Underlying: Common Stock · 5,171 shares Expires 2031-03-01 F1 · kind: On March 1, 2021 (the "Effective Date"), Mr. Ron A. Andrews (the "Reporting Person") was appointed to the Board of Directors of Precipio, Inc. (the "Company"). In connection with the Reporting Person's appointment and pursuant to the Company's 2017 Stock Option and Incentive Plan, the Company issued to the Reporting Person options (each an "Option" and together, the "Options") to purchase 2,069 and 5,171 shares, respectively, of the Company's common stock, par value $0.01 per share, both at an exercise price of $2.60 (the closing price of the Company's common stock on the Effective Date). F1 · price: On March 1, 2021 (the "Effective Date"), Mr. Ron A. Andrews (the "Reporting Person") was appointed to the Board of Directors of Precipio, Inc. (the "Company"). In connection with the Reporting Person's appointment and pursuant to the Company's 2017 Stock Option and Incentive Plan, the Company issued to the Reporting Person options (each an "Option" and together, the "Options") to purchase 2,069 and 5,171 shares, respectively, of the Company's common stock, par value $0.01 per share, both at an exercise price of $2.60 (the closing price of the Company's common stock on the Effective Date). F3 · derivative.exercise_date: The Option vests in thirty-six equal monthly installments beginning on the Effective Date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 20:08 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantEmployee Stock Option (right to buy) · Derivative | 2,069 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-21-032065 · tm215617d2_4.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,069 Underlying: Common Stock · 2,069 shares Expires 2031-03-01 F1 · kind: On March 1, 2021 (the "Effective Date"), Mr. Ron A. Andrews (the "Reporting Person") was appointed to the Board of Directors of Precipio, Inc. (the "Company"). In connection with the Reporting Person's appointment and pursuant to the Company's 2017 Stock Option and Incentive Plan, the Company issued to the Reporting Person options (each an "Option" and together, the "Options") to purchase 2,069 and 5,171 shares, respectively, of the Company's common stock, par value $0.01 per share, both at an exercise price of $2.60 (the closing price of the Company's common stock on the Effective Date). F1 · price: On March 1, 2021 (the "Effective Date"), Mr. Ron A. Andrews (the "Reporting Person") was appointed to the Board of Directors of Precipio, Inc. (the "Company"). In connection with the Reporting Person's appointment and pursuant to the Company's 2017 Stock Option and Incentive Plan, the Company issued to the Reporting Person options (each an "Option" and together, the "Options") to purchase 2,069 and 5,171 shares, respectively, of the Company's common stock, par value $0.01 per share, both at an exercise price of $2.60 (the closing price of the Company's common stock on the Effective Date). F2 · derivative.exercise_date: The Option vests in twelve equal monthly installments beginning on the Effective Date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:28 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $5.34 Strike: $5.34 | $2,670,000.00 |
DisclosureSEC source: 0001493152-21-005098 · ownership.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-02-24 F1 · derivative.exercise_date: Vesting: Twenty-five percent of the options will vest and thereby become exercisable upon completion of one year of service from the date of grant, and the balance of the options will vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, subject to his continued service as an employee on the applicable vesting date. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 22:50 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 40,000 | $1.35 | $53,880.00 |
DisclosureSEC source: 0001493152-20-014613 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,698 F1 · price: The shares were purchased at various prices ranging from $1.32 to $1.40. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:05 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantShare Option (Right to Buy) · Derivative | 9,494 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001437749-20-013988 · rdgdoc.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,494 Underlying: Ordinary Shares · 9,494 shares Expires 2030-06-24 F1 · security: Options granted under Issuer's 2013 Share Incentive Plan. F2 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the underlying shares on the earlier of the first anniversary of the date of grant or the date of the first annual general meeting of the shareholders held after the date of grant. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:05 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantOrdinary Shares | 4,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-013988 · rdgdoc.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,081 Read SEC document |
| May 07, 2020 Filed May 12, 2020 18:25 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantRestricted Stock Units · Derivative | 106,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-008357 · ownership.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,221 Underlying: Common Stock · 106,221 shares Expires not disclosed F1 · derivative.exercise_price: Grant of restricted stock units under the OncoCyte 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant. F2 · derivative.expiration_date: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 01:24 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 18,000 | $2.37 | $42,696.00 |
DisclosureSEC source: 0001493152-20-005646 · ownership.xml · nonDerivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,698 F1 · price: Amendment to correct March 31, 2020 share purchase price by replacing erroneous comma with a decimal point. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 20:05 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 18,000 | $2,372.00 | $42,696,000.00 |
DisclosureSEC source: 0001493152-20-005608 · ownership.xml · nonDerivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,698 Read SEC document |
| March 30, 2020 Filed Apr 2, 2020 01:24 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 27,216 | $2.26 | $61,453.73 |
DisclosureSEC source: 0001493152-20-005646 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,698 Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 20:05 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 27,216 | $2.26 | $61,453.73 |
DisclosureSEC source: 0001493152-20-005608 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,698 Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 22:44 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 950,000 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001209191-19-041282 · doc4.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,000 Underlying: Common Stock · 950,000 shares Expires 2029-06-30 F1 · derivative.exercise_date: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on July 1, 2019 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantSHARE OPTION (RIGHT TO BUY) · Derivative | 7,457 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001437749-19-012282 · rdgdoc.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457 Underlying: ORDINARY SHARES · 7,457 shares Expires 2029-06-18 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant. Read SEC document |
| August 30, 2018 Filed Sep 5, 2018 01:40 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001209191-18-049412 · doc4.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-08-29 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| July 26, 2018 Filed Aug 1, 2018 01:39 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock purchase warrants · Derivative | 17,482 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001493152-18-010765 · ownership.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,482 Underlying: Common stock · 17,482 shares Expires 2024-02-01 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| July 26, 2018 Filed Aug 1, 2018 01:39 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock, no par value | 17,482 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-010765 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,482 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantSHARE OPTION (RIGHT TO BUY) · Derivative | 7,457 | $0.00 Strike: $14.49 | $0.00 |
DisclosureSEC source: 0001437749-18-012232 · rdgdoc.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457 Underlying: ORDINARY SHARES · 7,457 shares Expires 2028-06-19 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 20:33 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantSHARE OPTION (RIGHT TO BUY) · Derivative | 7,457 | $0.00 Strike: $14.46 | $0.00 |
DisclosureSEC source: 0001437749-17-010976 · rdgdoc.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457 Underlying: ORDINARY SHARES · 7,457 shares Expires 2027-06-06 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.